OXYTETRACYCLINE ANHYDROUS

US Approved OTC

First approved in 1950

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H24N2O9
Molecular Weight	460.434
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C

InChI

InChIKey=IWVCMVBTMGNXQD-PXOLEDIWSA-N

InChI=1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25,27-29,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.newegg.com/Product/Product.aspx?Item=9SIA10N08P4475

Oxytetracycline, a tetracycline analog isolated from the actinomycete streptomyces rimosus, was the second of the broad-spectrum tetracycline group of antibiotics to be discovered The drug is used for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms for animal use only. These infections include the following: Ocular infections due to streptococci, rickettsiae E. coli, and A. aerogenes (such as conjunctivitis, keratitis, pinkeye, corneal ulcer, and blepharitis in dogs); ocular infections due to secondary bacterial complications associated with distemper in dogs; and ocular infections due to bacterial inflammatory conditions which may occur secondary to other diseases in dogs. Allergic reactions may occasionally occur. Treatment should be discontinued if reactions are severe. If new infections due to nonsensitive bacteria or fungi appear during therapy, appropriate measures should be taken. Oxytetracycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Oxytetracycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial 70S ribosome 179 Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6163479	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Superficial ocular infections 6 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2623f078-1ce0-4ae3-98c5-657971bad554	Curative		Approved 8429	TERRAMYCIN W/ POLYMYXIN B SULFATE Approved Use Terramycin Ophthalmic Ointment with Polymyxin B Sulfate is indicated for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms, including infections due to streptococci, rickettsiae, E. coli, and A. aerogenes, such as conjunctivitis, keratitis, pink eye, corneal ulcer, blepharitis in dogs, cats, cattle, sheep, and horses; ocular infections due to secondary bacterial complications of distemper in dogs, and bacterial inflammatory conditions which may occur secondary to other infectious diseases in the above species.

C_max

Value	Dose	Co-administered	Analyte	Population
15 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31185241/	250 mg/kg bw single, oral dose: 250 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		OXYTETRACYCLINE plasma	Oryctolagus cuniculus population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
90.72 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31185241/	250 mg/kg bw single, oral dose: 250 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		OXYTETRACYCLINE plasma	Oryctolagus cuniculus population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.46 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31185241/	250 mg/kg bw single, oral dose: 250 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		OXYTETRACYCLINE plasma	Oryctolagus cuniculus population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	Other AEs: Nausea, Diarrhoea... Other AEs: Nausea (grade 1-2, 15 patients) Diarrhoea (grade 1-2, 13 patients) Rash (grade 1-2, 1 patient) Lassitude (grade 1-2, 1 patient) Nausea (grade 3, 10 patients) Diarrhoea (grade 3, 5 patients) Nausea (grade 4, 1 patient) Diarrhoea (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/

AEs

AE	Significance	Dose	Population
Lassitude	grade 1-2, 1 patient	250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/
Rash	grade 1-2, 1 patient	250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/
Diarrhoea	grade 1-2, 13 patients	250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/
Nausea	grade 1-2, 15 patients	250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/
Nausea	grade 3, 10 patients	250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/
Diarrhoea	grade 3, 5 patients	250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/
Diarrhoea	grade 4, 1 patient	250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/
Nausea	grade 4, 1 patient	250 mg 4 times / day steady, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: steady Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/	unhealthy, adult n = 369 Health Status: unhealthy Condition: cough and cold Age Group: adult Sex: unknown Population Size: 369 Sources: https://pubmed.ncbi.nlm.nih.gov/3524647/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT1 599 OAT2 145 OAT3 642 OAT4 146	P-gp 1537

Drug as perpetrator

Target	Modality	Activity
OAT3 644	inhibitor 3277 Sources: https://pdf.sciencedirectassets.com/321778/1-s2.0-S0021519802X88015/1-s2.0-S002151981930232X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEJT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG8xtAfIkZJ4AlA2a36IQc%2BSLoD1G3HkvXaeOIKxsHraAiBjR9tS4TUe6guLfOlo%2FUmJWT64itdQG2u5YqX78wGPyiq0AwgdEAMaDDA1OTAwMzU0Njg2NSIMG94UL2%2BWaFnvr6sXKpEDG1M9rrsyHLz9BacpjEPAwBRIT1JCiQUKQk3efOrleNC%2Bw41D4ydrYNNzK7MniRZuFt0camn2GE%2BUKCZk3Om8Xsizv8RZ5rkyeq9E4v5Om7LfXVIn3MCmIFonFfJ8Ajc1u4ra7IwuCHsQNZMSShD%2FrjQ%2FdkzfpNlHKEq3nzTs2agGiJpkPSUKwxYNcoFcVfnq09hrVKG2fEwTXnHlaCurfPnwgk5ZLtZ%2FPr7fnDJTu68ChRCEZ6kmV6kUO5O2emge9Nc7Lg5Kcdb34rN3DaSMIvApK7xC9ulH%2BgdEFWXcSukxgCrwSBgl6x2Z8gklcRV6hplsJU%2F5SzBt8vx%2BLopHCdPdTymtjNj3eUTqa7zcKUR3S3Bg88kGZniPWj4zZkxV7qJiSN7r%2Bi%2B2nOc9%2FkGApsKwoP2yYbiUouGdF0%2B6j4xYxb0LbREJitI39AFMOd4Ku3%2Bvv9dK7ZpF4Bs8%2FiHP6qdi7byO3hjz2c0THEApSOINiakQhRJRj6QnbUDYmqyLNm4LuEe7ClW24xxRDVTn384wg%2B%2FLhAY67AEAnh3M95X0TU4C54ovJq%2FbhSMse9rMxFpZmH5YM2QOiNkYAFBhePQqJYa7fiptog7SnGWw55zvtI1CY%2F6vIqHAQJLnsG9LtiVo8a0v5jIfMimOwxTJp6jqNVc49bQq7nocIwgqqljmwiNHoMer9A4USjHsE%2B%2FFQqmPx098VcpPXzNC7VFex7AYelXD37QJer9G%2Fcub9NbrO6Fs3Bdw9%2BMVUpgk97H%2Bs%2BV17BV%2FbJ6BsgscUHOqBV1FPHCjWeJGHASSkDjCejQOZ3DWvfEMKXV1KFiXhEBubBj5bA1O7ofdGkI%2FbgDBQNqAP0IvNQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210505T205352Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYTDR3UALE%2F20210505%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=f13809be6576e6ebde957fc5e2c856013e46b335cc152ab7b1ea852f70c74765&hash=ea62c833a8cfcae9cd43b5c5a07a7d73e316028cff36ab0b48cd05c2a9a3f794&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S002151981930232X&tid=spdf-c9c84b45-f446-44d0-a0ec-3af2b59c8c67&sid=3cc0cf6127cbc24a36990b3293a507acc1ffgxrqa&type=client Page: 1.0	no
OAT4 146	inhibitor 3277 Sources: https://pdf.sciencedirectassets.com/321778/1-s2.0-S0021519802X88015/1-s2.0-S002151981930232X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEJT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG8xtAfIkZJ4AlA2a36IQc%2BSLoD1G3HkvXaeOIKxsHraAiBjR9tS4TUe6guLfOlo%2FUmJWT64itdQG2u5YqX78wGPyiq0AwgdEAMaDDA1OTAwMzU0Njg2NSIMG94UL2%2BWaFnvr6sXKpEDG1M9rrsyHLz9BacpjEPAwBRIT1JCiQUKQk3efOrleNC%2Bw41D4ydrYNNzK7MniRZuFt0camn2GE%2BUKCZk3Om8Xsizv8RZ5rkyeq9E4v5Om7LfXVIn3MCmIFonFfJ8Ajc1u4ra7IwuCHsQNZMSShD%2FrjQ%2FdkzfpNlHKEq3nzTs2agGiJpkPSUKwxYNcoFcVfnq09hrVKG2fEwTXnHlaCurfPnwgk5ZLtZ%2FPr7fnDJTu68ChRCEZ6kmV6kUO5O2emge9Nc7Lg5Kcdb34rN3DaSMIvApK7xC9ulH%2BgdEFWXcSukxgCrwSBgl6x2Z8gklcRV6hplsJU%2F5SzBt8vx%2BLopHCdPdTymtjNj3eUTqa7zcKUR3S3Bg88kGZniPWj4zZkxV7qJiSN7r%2Bi%2B2nOc9%2FkGApsKwoP2yYbiUouGdF0%2B6j4xYxb0LbREJitI39AFMOd4Ku3%2Bvv9dK7ZpF4Bs8%2FiHP6qdi7byO3hjz2c0THEApSOINiakQhRJRj6QnbUDYmqyLNm4LuEe7ClW24xxRDVTn384wg%2B%2FLhAY67AEAnh3M95X0TU4C54ovJq%2FbhSMse9rMxFpZmH5YM2QOiNkYAFBhePQqJYa7fiptog7SnGWw55zvtI1CY%2F6vIqHAQJLnsG9LtiVo8a0v5jIfMimOwxTJp6jqNVc49bQq7nocIwgqqljmwiNHoMer9A4USjHsE%2B%2FFQqmPx098VcpPXzNC7VFex7AYelXD37QJer9G%2Fcub9NbrO6Fs3Bdw9%2BMVUpgk97H%2Bs%2BV17BV%2FbJ6BsgscUHOqBV1FPHCjWeJGHASSkDjCejQOZ3DWvfEMKXV1KFiXhEBubBj5bA1O7ofdGkI%2FbgDBQNqAP0IvNQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210505T205352Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYTDR3UALE%2F20210505%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=f13809be6576e6ebde957fc5e2c856013e46b335cc152ab7b1ea852f70c74765&hash=ea62c833a8cfcae9cd43b5c5a07a7d73e316028cff36ab0b48cd05c2a9a3f794&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S002151981930232X&tid=spdf-c9c84b45-f446-44d0-a0ec-3af2b59c8c67&sid=3cc0cf6127cbc24a36990b3293a507acc1ffgxrqa&type=client Page: 1.0	no
OAT2 147	inhibitor 3277 Sources: https://pdf.sciencedirectassets.com/321778/1-s2.0-S0021519802X88015/1-s2.0-S002151981930232X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEJT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG8xtAfIkZJ4AlA2a36IQc%2BSLoD1G3HkvXaeOIKxsHraAiBjR9tS4TUe6guLfOlo%2FUmJWT64itdQG2u5YqX78wGPyiq0AwgdEAMaDDA1OTAwMzU0Njg2NSIMG94UL2%2BWaFnvr6sXKpEDG1M9rrsyHLz9BacpjEPAwBRIT1JCiQUKQk3efOrleNC%2Bw41D4ydrYNNzK7MniRZuFt0camn2GE%2BUKCZk3Om8Xsizv8RZ5rkyeq9E4v5Om7LfXVIn3MCmIFonFfJ8Ajc1u4ra7IwuCHsQNZMSShD%2FrjQ%2FdkzfpNlHKEq3nzTs2agGiJpkPSUKwxYNcoFcVfnq09hrVKG2fEwTXnHlaCurfPnwgk5ZLtZ%2FPr7fnDJTu68ChRCEZ6kmV6kUO5O2emge9Nc7Lg5Kcdb34rN3DaSMIvApK7xC9ulH%2BgdEFWXcSukxgCrwSBgl6x2Z8gklcRV6hplsJU%2F5SzBt8vx%2BLopHCdPdTymtjNj3eUTqa7zcKUR3S3Bg88kGZniPWj4zZkxV7qJiSN7r%2Bi%2B2nOc9%2FkGApsKwoP2yYbiUouGdF0%2B6j4xYxb0LbREJitI39AFMOd4Ku3%2Bvv9dK7ZpF4Bs8%2FiHP6qdi7byO3hjz2c0THEApSOINiakQhRJRj6QnbUDYmqyLNm4LuEe7ClW24xxRDVTn384wg%2B%2FLhAY67AEAnh3M95X0TU4C54ovJq%2FbhSMse9rMxFpZmH5YM2QOiNkYAFBhePQqJYa7fiptog7SnGWw55zvtI1CY%2F6vIqHAQJLnsG9LtiVo8a0v5jIfMimOwxTJp6jqNVc49bQq7nocIwgqqljmwiNHoMer9A4USjHsE%2B%2FFQqmPx098VcpPXzNC7VFex7AYelXD37QJer9G%2Fcub9NbrO6Fs3Bdw9%2BMVUpgk97H%2Bs%2BV17BV%2FbJ6BsgscUHOqBV1FPHCjWeJGHASSkDjCejQOZ3DWvfEMKXV1KFiXhEBubBj5bA1O7ofdGkI%2FbgDBQNqAP0IvNQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210505T205352Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYTDR3UALE%2F20210505%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=f13809be6576e6ebde957fc5e2c856013e46b335cc152ab7b1ea852f70c74765&hash=ea62c833a8cfcae9cd43b5c5a07a7d73e316028cff36ab0b48cd05c2a9a3f794&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S002151981930232X&tid=spdf-c9c84b45-f446-44d0-a0ec-3af2b59c8c67&sid=3cc0cf6127cbc24a36990b3293a507acc1ffgxrqa&type=client Page: 5.0	yes [Inhibition 5 uM]
OAT1 603	inhibitor 3277 Sources: https://pdf.sciencedirectassets.com/321778/1-s2.0-S0021519802X88015/1-s2.0-S002151981930232X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEJT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG8xtAfIkZJ4AlA2a36IQc%2BSLoD1G3HkvXaeOIKxsHraAiBjR9tS4TUe6guLfOlo%2FUmJWT64itdQG2u5YqX78wGPyiq0AwgdEAMaDDA1OTAwMzU0Njg2NSIMG94UL2%2BWaFnvr6sXKpEDG1M9rrsyHLz9BacpjEPAwBRIT1JCiQUKQk3efOrleNC%2Bw41D4ydrYNNzK7MniRZuFt0camn2GE%2BUKCZk3Om8Xsizv8RZ5rkyeq9E4v5Om7LfXVIn3MCmIFonFfJ8Ajc1u4ra7IwuCHsQNZMSShD%2FrjQ%2FdkzfpNlHKEq3nzTs2agGiJpkPSUKwxYNcoFcVfnq09hrVKG2fEwTXnHlaCurfPnwgk5ZLtZ%2FPr7fnDJTu68ChRCEZ6kmV6kUO5O2emge9Nc7Lg5Kcdb34rN3DaSMIvApK7xC9ulH%2BgdEFWXcSukxgCrwSBgl6x2Z8gklcRV6hplsJU%2F5SzBt8vx%2BLopHCdPdTymtjNj3eUTqa7zcKUR3S3Bg88kGZniPWj4zZkxV7qJiSN7r%2Bi%2B2nOc9%2FkGApsKwoP2yYbiUouGdF0%2B6j4xYxb0LbREJitI39AFMOd4Ku3%2Bvv9dK7ZpF4Bs8%2FiHP6qdi7byO3hjz2c0THEApSOINiakQhRJRj6QnbUDYmqyLNm4LuEe7ClW24xxRDVTn384wg%2B%2FLhAY67AEAnh3M95X0TU4C54ovJq%2FbhSMse9rMxFpZmH5YM2QOiNkYAFBhePQqJYa7fiptog7SnGWw55zvtI1CY%2F6vIqHAQJLnsG9LtiVo8a0v5jIfMimOwxTJp6jqNVc49bQq7nocIwgqqljmwiNHoMer9A4USjHsE%2B%2FFQqmPx098VcpPXzNC7VFex7AYelXD37QJer9G%2Fcub9NbrO6Fs3Bdw9%2BMVUpgk97H%2Bs%2BV17BV%2FbJ6BsgscUHOqBV1FPHCjWeJGHASSkDjCejQOZ3DWvfEMKXV1KFiXhEBubBj5bA1O7ofdGkI%2FbgDBQNqAP0IvNQ%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210505T205352Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYTDR3UALE%2F20210505%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=f13809be6576e6ebde957fc5e2c856013e46b335cc152ab7b1ea852f70c74765&hash=ea62c833a8cfcae9cd43b5c5a07a7d73e316028cff36ab0b48cd05c2a9a3f794&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S002151981930232X&tid=spdf-c9c84b45-f446-44d0-a0ec-3af2b59c8c67&sid=3cc0cf6127cbc24a36990b3293a507acc1ffgxrqa&type=client Page: 5.0	yes [Inhibition 500 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2885.2007.00808.x Page: 1.0	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0017	http://www.3bsc.com/index/pro_info.php?id=19373
3B Scientific (Wuhan) Corp	3B1-01360	http://www.3bsc.com/index/pro_info.php?id=21572
AA Blocks	AA019FPP	https://www.aablocks.com/goods/Goods/detail?id=AA019FPP
AHH Chemical co.,ltd	API-1016	http://www.ahhchemical.com/product/API-1016.html
AHH Chemical co.,ltd	MT-57611	http://www.ahhchemical.com/product/MT-57611.html
AK Scientific, Inc. (AKSCI)	S470	http://www.aksci.com/item_detail.php?cat=S470
Aaron Chemicals	AR019GHH	http://www.aaronchem.com/79-57-2
AbMole Bioscience	M3540	http://www.abmole.com/products/oxytetracycline.html
Acros Organics	AC257700025	https://www.fishersci.com/shop/products/oxytetracycline-can-be-used-as-secondarystandard-acros-organics-1/AC257700025
Acros Organics	AC257705000	https://www.fishersci.com/shop/products/oxytetracycline-can-be-used-as-secondarystandard-acros-organics/AC257705000
Ambeed	A149568	https://www.ambeed.com/products/79-57-2.html
ApexBio Technology	B2000	http://www.apexbt.com/oxytetracycline-terramycin.html
Aurora Fine Chemicals LLC	A17.902.494	http://online.aurorafinechemicals.com/info?ID=A17.902.494
Aurora Fine Chemicals LLC	K16.602.293	http://online.aurorafinechemicals.com/info?ID=K16.602.293
BLD Pharm	BD146584	http://www.bldpharm.com/products/79-57-2.html
BioCrick	BCC4819	http://www.biocrick.com/Oxytetracycline-Terramycin-BCC4819.html
Boerchem	BC202856	http://www.boerchem.com/?product_34086.html
CSNpharm	CSN11640	https://www.csnpharm.com/products/oxytetracycline.html
Chem Scene	CS-2265	http://www.chemscene.com/79-57-2.html
ChemMol	30102484	http://www.chemmol.com/chemmol/30102484.html
ChemMol	30103089	http://www.chemmol.com/chemmol/30103089.html
ChemMol	44001363	http://www.chemmol.com/chemmol/44001363.html
ChemMol	49416799	http://www.chemmol.com/chemmol/49416799.html
ChemShuttle	151504	http://www.chemshuttle.com/catalogsearch/result/?q=79-57-2&cat=
Chemspace	CSSB00020618728	https://chem-space.com/CSSB00020618728
Hairui	HR138559	http://www.hairuichem.com/en/product/6153-64-6.html
Lab Network	LN01291958	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01291958
MedChem Express	HY-B0275	https://www.medchemexpress.com/Oxytetracycline.html
MolPort	MolPort-002-524-946	https://www.molport.com/shop/molecule-link/MolPort-002-524-946
MolPort	MolPort-005-934-326	https://www.molport.com/shop/molecule-link/MolPort-005-934-326
MuseChem	A000493	https://www.musechem.com/product/A000493.html
MuseChem	R065745	https://www.musechem.com/product/R065745.html
Parchem	38568	https://www.parchem.com/chemical-supplier-distributor/Oxytetracycline-038568.aspx
Selleck Chemicals	S1773	http://www.selleckchem.com/products/Oxytetracycline(Terramycin).html
Sigma-Aldrich	51239_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/51239?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP782_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp782?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	O0400000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/o0400000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
VladaChem	VL276549-100MG	https://www.vladachem.com/product.php?products=79-57-2
Yuhao Chemical	HL2111	http://www.chemyuhao.com/2058-46-0.html
Yuhao Chemical	LT7267	http://www.chemyuhao.com/6153-64-6.html
Yuhao Chemical	XJ0093	http://www.chemyuhao.com/79-57-2.html
abcr GmbH	AB347674	http://www.abcr.com/shop/en/AB347674
eNovation Chemicals	D388845	https://www.enovationchem.com/ProductDetails.asp?ProductID=D388845
eNovation Chemicals	D672229	https://www.enovationchem.com/ProductDetails.asp?ProductID=D672229
eNovation Chemicals	D767117	https://www.enovationchem.com/ProductDetails.asp?ProductID=D767117
mcule	MCULE-5398230579	https://mcule.com/MCULE-5398230579/

PubMed

Title	Date	PubMed
[Acute renal failure following overdosage of oxyterracin].	1970 Jan	5413699
Azotaemia aggravated by tetracycline.	1970 Jan 3	5411600
Azotaemia aggravated by oxytetracycline.	1971 Nov 16	5140825
Case report: coma due to oxytetracycline.	1977	598213
Oxytetracycline nephrotoxicosis in two dogs.	1980 Mar 15	7364640
Screening for new compounds with antiherpes activity.	1984 Oct	6517562
Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.	1988 Feb	2452149
In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs.	1990 Aug	2221857
Contact allergies to topical corticosteroids.	1993 Mar	8462297
Cholestatic hepatitis associated with flucloxacillin.	1993 May 3	8479374
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.	1996 Dec	9039272
Minocycline-induced chronic interstitial nephritis?	1996 Mar	8671830
Oxytetracycline-induced nephrotoxicosis in dogs after intravenous administration for experimental bone labeling.	1996 Oct	8905581
Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets.	2000 Oct	11058033
Human organic anion transporters mediate the transport of tetracycline.	2002 Jan	11855680
In vitro effects of oxytetracycline on matrix metalloproteinase-1 mRNA expression and on collagen gel contraction by cultured myofibroblasts obtained from the accessory ligament of foals.	2004 Apr	15077693
Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.	2005 Jul	15963097
Drug treatment during pregnancy and isolated orofacial clefts in hungary.	2007 Mar	17328645
Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.	2010 Jul	20116850
Impact of isoflupredone acetate treatment on clinical signs and weight gain in weanling heifers with experimentally induced Mannheimia haemolytica bronchopneumonia.	2011 Dec	22126689
Environmental impact on vascular development predicted by high-throughput screening.	2011 Nov	21788198
Effect of pharmaceuticals exposure on acetylcholinesterase (AchE) activity and on the expression of AchE gene in the monogonont rotifer, Brachionus koreanus.	2013 Nov	24028855
Molecular and Cellular Effects Induced in Mytilus galloprovincialis Treated with Oxytetracycline at Different Temperatures.	2015	26067465

Patents

Sample Use Guides

In Vivo Use Guide

For Animal Use Only: topically to the eye 2–4 times daily.

Route of Administration: Other

In Vitro Use Guide

It was investigated the possible toxic mechanism of oxytetracycline (OTC) on the human red blood cells (hRBCs). The experimental results indicate that OTC can cause a decline in the function of the antioxidant defense system of hRBCs, resulting in oxidative stress. OTC can bring about morphological changes to hRBCs, and further leads to hemolysis, when the concentration of OTC is over 8×10(-5) M (about 164 µg/ml). At a low OTC concentration, below 4×10(-5) M (82 µg/ml), OTC can enhance the activity of ATP enzyme of hRBCs, known as hormesis. However, at a high concentration, above 4×10(-5) M (about 82 µg/ml), the ATP enzymatic activity was inhibited, affecting the function of hRBCs.

Name

Type

Language

OXYTETRACYCLINE ANHYDROUS

Common Name

English

oxytetracycline [INN]

Common Name

English

DOXYCYCLINE IMPURITY E

Common Name

English

DOXYCYCLINE MONOHYDRATE IMPURITY E [EP IMPURITY]

Common Name

English

(4S,4AR,5S,5AR,6S,12AS)-4-(DIMETHYLAMINO)-3,5,6,10,12,12AHEXAHYDROXY-6-METHYL-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE

Common Name

English

Oxytetracycline [WHO-DD]

Common Name

English

2-NAPHTHACENECARBOXAMIDE, 4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,5,6,10,12,12A-HEXAHYDROXY-6-METHYL-1,11-DIOXO-, (4S-(4.ALPHA.,4A.ALPHA.,5.ALPHA.,5A.ALPHA.,6.BETA.,12A.ALPHA.))-

Common Name

English

4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,5,6,10,12,12A-HEXAHYDROXY-6-METHYL-1,11-DIOXO-2-NAPHTHACENECARBOXAMIDE

Common Name

English

DOXYCYCLINE HYCLATE IMPURITY E [EP IMPURITY]

Common Name

English

NSC-9169

Code

English

OXYTETRACYCLINE (ANHYDROUS) [HSDB]

Common Name

English

OXYTETRACYCLINE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1595